News Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19 Staff September 11, 2023 Iframe sync Post navigation Previous: Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research ConferenceNext: Major shareholder announcement – BlackRock, Inc. More Stories Healthcare News XRP Healthcare® Secures Global Trademark Protection at the Intersection of Healthcare Services and XRP-Powered Payments Staff December 22, 2025 Healthcare News Pharmaceutical Black Book Poll: “Governed AI” Emerges as the Deciding Factor in 2026 NHS Procurement Staff December 22, 2025 Healthcare News Pharmaceutical Hemogenyx Pharmaceuticals PLC Announces Update on Admission of Shares Staff December 22, 2025
